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IntroDuCtIon
Brain tumours are the biggest cause of death from cancer 
in children.1 Radiological assessment is one of the key 
tools used in the management of this patient cohort. 
The primary imaging modality now employed is MRI 
which provides a clear picture of the internal soft tissue 
structure of the brain. Advanced MRI techniques are 
able to probe metabolism, blood flow and cellularity via 
a range of methods.2 Perfusion MRI, which provides 
estimates of cerebral blood flow (CBF) and relative cere-
bral blood volume (rCBV), has become increasingly 
pertinent as the use of antivascular and anti-angiogenic 
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objective: To investigate correlations between MRI 
perfusion metrics measured by dynamic susceptibility 
contrast and arterial spin labelling in paediatric brain 
tumours.
Methods: 15 paediatric patients with brain tumours 
were scanned prospectively using pseudo-continuous 
arterial spin labelling (ASL) and dynamic suscepti-
bility contrast (DSC-) MRI with a pre-bolus to mini-
mise contrast agent leakage. Cerebral blood flow 
(CBF) maps were produced using ASL. Cerebral blood 
volume (CBV) maps with and without contrast agent 
leakage correction using the Boxerman technique and 
the leakage parameter, K2, were produced from the 
DSC data. Correlations between the metrics produced 
were investigated.
results: Histology resulted in the following diagnoses: 
pilocytic astrocytoma (n = 7), glioblastoma (n = 1), 
medulloblastoma (n = 1), rosette-forming glioneuronal 
tumour of fourth ventricle (n = 1), atypical choroid plexus 
papilloma (n = 1) and pilomyxoid astrocytoma (n = 1). 
Three patients had a non-invasive diagnosis of low-grade 
glioma. DSC CBV maps of T1-enhancing tumours were 
difficult to interpret without the leakage correction. 
CBV values obtained with and without leakage correc-
tion were significantly different (p < 0.01). A significant 
positive correlation was observed between ASL CBF and 
DSC CBV (r = 0.516, p = 0.049) which became stronger 
when leakage correction was applied (r = 0.728, p = 
0.002). K2 values were variable across the group (mean 
= 0.35, range = −0.49 to 0.64).
Conclusion: CBV values from DSC obtained with and 
without leakage correction were significantly different. 
Large increases in CBV were observed following leakage 
correction in highly T1-enhancing tumours. DSC and ASL 
perfusion metrics were found to correlate significantly 
in a range of paediatric brain tumours. A stronger rela-
tionship between DSC and ASL was seen when leakage 
correction was applied to the DSC data. Leakage correc-
tion should be applied when analysing DSC data in 
enhancing paediatric brain tumours.
advances in knowledge: We have shown that leakage 
correction should be applied when investigating 
enhancing paediatric brain tumours using DSC-MRI. A 
stronger correlation was found between CBF derived 
from ASL and CBV derived from DSC when a leakage 
correction was employed.
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treatments are becoming more commonplace3 and has demon-
strated relationships with tumour grade4,5 and long-term 
survival.6
Two widely-used methods for measuring perfusion in the brain 
are dynamic susceptibility contrast (DSC-) MRI and arterial spin 
labelling (ASL). DSC-MRI involves the injection of a contrast 
agent followed by rapid tracking of the bolus via MR imaging.7 
The use of DSC-MRI has been reported in paediatrics5,8 but a 
number of issues have prevented it from being implemented 
routinely, such as the requirement of a cannula and pressure 
injector, increasing concerns over the use of gadolinium contrast 
agents9 and the need for an arterial input function for fully 
quantitative analysis.10 DSC data analysis methods11 assume 
that the injected contrast agent remains intravascular so that the 
effects of contrast agent on T1 can be ignored. rCBV can there-
fore be calculated as the area underneath the change in effective 
transverse relaxation time, ΔR2*, graph. This is not the case in 
many brain tumours due to blood brain barrier breakdown.12 
Leakage of contrast agent into the extravascular extracellular 
space (EES) during the DSC scan affects the signals produced 
in two competing ways. Contrast agent shortens T1 values 
of tissue water within the EES, resulting in an increase in MR 
signal during the DSC scan which competes with the MR signal 
arising due to intravascular contrast agent and resulting in an 
underestimation of rCBV. Conversely, T2/T2* effects arise due 
to changes in susceptibility differences between the EES and 
intravascular compartments reducing the MR signal so that it 
does not recover to baseline during the DSC scan. This results 
in overestimation of rCBV. Where contrast agent extravasation 
is particularly rapid rCBV can be calculated as negative as the 
signal increase due to T1 effects is greater than the signal reduc-
tion due to T2* effects. Leakage effects can be addressed by giving 
a loading dose of contrast agent prior to the DSC acquisition,13,14 
careful choice of sequence parameters to minimise the effect of 
leakage on the signal-time course14,15 and by using post-pro-
cessing methods to correct for contrast agent leakage.16–20 The 
Boxerman technique16,19 uses the signal-time course obtained 
from a whole-brain mask of non-enhancing pixels to correct the 
leakage-affected DSC signal-time course, resulting in a corrected 
cerebral blood volume (CBV). A parameter representing the 
amount of leakage that has taken place, K2, is also obtained.
ASL does not require an injection of contrast agent, instead 
using a labelling slice placed in the neck to label blood flowing 
into the imaging volume.21 ASL has yet to establish itself into 
routine clinical practice due to its inherently low signal-to-
noise-ratio (SNR), limited spatial resolution, a lack of harmon-
isation between the protocols available on different scanners 
and limited clinical evidence of usefulness. Modern hardware 
improvements including the increased availability of 3T scan-
ners and pulse sequence development including pseudo-con-
tinuous ASL (pCASL),22 Look-Locker23 and combined gradient 
and spin echo24 readouts have, in part, addressed SNR and scan 
length limitations. The recent publication of a consensus paper 
on recommended clinical protocols has provided a solid founda-
tion for ASL to be implemented clinically in both adults and chil-
dren.21 The recommendations clearly point to the use of pCASL, 
preferably with a three-dimensional readout. This is due to the 
high SNR afforded by the labelling scheme/readout combination 
and also the near-complete head coverage that can be achieved in 
a clinically-acceptable timescale.21
The lack of requirement for contrast agent administration in ASL 
imaging is an obvious advantage over DSC-MRI in the imaging 
of paediatric brain tumours. It is important, however, to assess 
the relationship between techniques which provide measures of 
similar metrics. A previous study investigating paediatric brain 
tumours using ASL and DSC found significant correlations 
between metrics in grey matter but found no significant correla-
tion in tumours;25 however, leakage correction was not applied 
to the DSC data. A subsequent study has shown large differences 
in the extent of leakage correction between high- and low-grade 
paediatric brain tumours suggesting that leakage correction 
is important when analysing DSC data in paediatric brain 
tumours.26 Finally, Dallery et al27 showed differences in leakage 
correction parameters between high- and low-grade paediatric 
brain tumours, although differences between corrected CBV 
values were not presented.
In this study we compare CBV measured by DSC and CBF 
measured by ASL in paediatric brain tumour patients. We apply 
the Boxerman method of leakage correction19 and compare 
corrected and uncorrected DSC CBV maps to the ASL data to 
assess the importance of this post-processing step.
MethoDS anD MaterIalS
This prospective study was approved by the East Midlands-
Derby Research Ethics Committee (REC 04/MRE04/41), oper-
ating under the rules of Declaration of Helsinki 1975 (and as 
revised in 1983). Informed parental consent was obtained from 
all subjects. A total of 15 paediatric patients with a diagnosis of 
a brain tumour by the local Neuro-Oncology Multidisciplinary 
Team underwent additional ASL and DSC scans as part of an 
MRI performed for routine clinical assessment.
Patients
Patients were eligible for inclusion if they had a cannula in situ 
for administration of contrast agent via a power injector – this 
included those undergoing general anaesthetic (mostly those 
under 6 years of age and approximately 50% of our paediatric 
brain tumour cohort) or for clinical necessity (an additional 
10%)–residual tumour greater than 1 cm3 in volume, patients 
with tumours which were not located close to the brain stem 
and those without metal implants so that susceptibility arte-
facts would not render data unanalysable. These patients 
were scanned on an advanced imaging list (of which there are 
approximately three examinations per month) to allow for the 
additional time needed for research scans. Since the primary 
aim of the study was to compare DSC and ASL rather than to 
determine perfusion characteristics of the tumours, patients 
were eligible irrespective of the treatment which they had 
received up to the point of the MRI. All data was acquired on a 
Philips Achieva 3T TX system (Best, The Netherlands) using a 
32-channel head coil.
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Imaging protocol
Arterial spin labelling MRI
A pseudo-continuous ASL (pCASL) sequence was used. Six 
transverse slices with a thickness of 7 mm and a matrix size 
of 64 × 64 pixels and one post-labelling delay at 1400 ms were 
acquired using a flip angle of 40° and a single shot EPI readout 
with 30 averages. The voxel volume was 3.75 × 3.75 × 7 mm. The 
pCASL labelling slab was placed 20 mm below the imaging slices 
and had duration 1400 ms. Vascular crushing and background 
suppression were not used for this study as there is no established 
method for optimisation for these in both brain tumours and the 
paediatric population. M0 maps were acquired using the same 
parameters as the ASL images minus the pCASL labelling and 
with the repetition time (TR) increased to 10 s using a single 
average.
Dynamic susceptibility contrast MRI
Prior to the DSC scan a high-resolution T2 weighted turbo 
spin echo scan with the same coverage was acquired for the 
purpose of defining regions-of-interest (ROI) [TR/echo time 
(TE) = 4000/100 ms, matrix = 144 × 144]. The DSC-MRI scan 
was a transverse field-echo echo planar imaging scan (TR/TE = 
1865/40 ms, field-of-view (FOV) =240 × 240 mm, matrix = 96 × 
96, voxel volume = 2.5 × 2.5 x 3.5 mm) with flip angle of 20°. 30 
slices with a slice thickness of 3.5 mm each were acquired to cover 
the whole brain. The temporal resolution of the DSC scan was 
1.86 s which was repeated 60 times. Contrast agent (Dotarem, 
Guerbet, France) was administered via a power injector through 
a cannula inserted into a suitable vein. The total dose of contrast 
agent given was 0.1 mmol/kg in two stages – the first half-dose 
as a pre-bolus prior to the high-resolution T2 weighted acquisi-
tion to allow minimisation of T1 effects and the second half-dose 
at the start of time point six in the DSC data acquisition, with 
each injection followed by a volume of up to 10 mls of saline. The 
injection rate used was 3 ml s−1.
Pre- and post-contrast MRI
Pre- and post-contrast T1 weighted TSE scans were acquired 
with the following parameters (TR = 600–825 ms, TE = 10 ms, 
flip angle = 50–70o, field-of-view = 230 × 230 mm, matrix = 512 
× 512, voxel volume = 0.45 × 0.45 x 5 mm, number of slices = 
30–36).
Data analysis
Both DSC and ASL data analyses were performed using soft-
ware developed in-house written in the Python programming 
language (v2.7, Python Software Foundation, http://www. 
python. org).
Arterial Spin Labelling MRI
CBF maps were produced from the ASL images using the 
method suggested in the recent consensus paper.21 The ASL 
images acquired with labelling were subtracted from the control 
images – those acquired without labelling pulse - to produce a 
perfusion-weighted image. Quantification was achieved by using 
equation 1.
 
CBF = 6000·λ·(SIcontrol−SIlabel)·e
PLD
T1(blood)
2·α·T1(blood)·SIPD·(1−e)− τT1(blood)
[ml/100 g/min]
 
[1]
where λ is the blood-brain barrier partition coefficient (assumed to 
be 0.9 ml g–1), SIcontrol is the signal intensity of the control image, 
SIlabel is the signal intensity of the label image, T1 (blood) is the 
T1 value of arterial blood (assumed to be 1.650 s at 3T), TI1 is the 
post-labelling delay and α is the labelling efficiency assumed to be 
0.85. All assumed values were taken from Alsop et al.21
Dynamic susceptibility contrast MRI
Signal-time curves were obtained from the DSC time course on a 
pixel-by-pixel basis and converted to the change in T2* relaxation 
time, ΔR2*, using:
 
∆R2∗
(
t
)
= − 1TE ln
(
S
(
t
)
S
(
0
))
 
[2]
where S(t) and S(0) are the signal intensities at time, t, and 
baseline respectively and TE is the time-to-echo of the DSC 
sequence. The baseline signal intensity was calculated by aver-
aging the signal from the first six time points. Pixel-by-pixel 
uncorrected rCBV values were calculated by integrating over 
the △R2*-time curves. Corrected rCBV values were calculated 
using the method outlined in.16,19 In brief, this model takes into 
account both the T1 and T2 effects from contrast agent extrava-
sation and aims to correct for them. Corrected rCBV (rCBVcorr) 
is calculated by integrating over the corrected △R2*-time curves, 
△R2,corr*(t):
 ∆R2,corr∗
(
t
)
= ∆
∼
R
∗
2
(
t
)
+ K2
∫ t
0
−
∆R∗2
(
t′
)
dt′ [3]
where  ∆
∼
R
∗
2
(
t
)
  is the uncorrected ΔR2*,  
−
∆R∗2
(
t′
)
  is the ΔR2* 
obtained over the whole brain and therefore provides an esti-
mate of the ΔR2* without allowing for leakage and K2 is a term 
reflecting the effects of leakage on both T1 and T2* and is esti-
mated by fitting the uncorrected △ΔR2* to the following equation:
 ∆
∼
R2
(
t
) ≡ K1 · −∆R∗2 (t)− K2 ∫ t0 −∆R∗2 (t′) dt′ [4]
A positive K2 indicates that T1 effects dominate the resulting 
signal-time curve while a negative K2 indicates T2*-dominant 
effect.19 K1 is purely a constant of proportionality. K1 and K2 were 
both obtained by least-squares fitting of the uncorrected ΔR2* to 
equation 4 using the whole-brain average  
−
∆R∗2
(
t
)
  as obtained 
from non-enhancing pixels in the brain and excluding signal 
from the ventricles.
Pre- and post-contrast MRI
The pre- and post-contrast T1 weighted images were registered 
to one another using the MERIT module in MeVisLab (v2.8.2, 
MeVis Medical Solutions AG, Germany) and then reformatted 
to cover the same volume as the high-resolution T2 weighted 
images. An image of the level of contrast enhancement was 
computed using:
 
Contrast enhancement = Signalpost−contrast − Signalpre−contrastSignalpre−contrast ×100 
 [5]
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Regions of interest
ROI were drawn around the whole tumour by JN, a scientist with 
6 years’ research experience in paediatric brain tumours, on the 
high-resolution T2 weighted images using clinically-acquired 
MRI scans for reference. Large areas of cyst were excluded. All 
ROIs were checked and amended where necessary by a consul-
tant radiologist who is a member of the Neuro-Oncology Multi-
disciplinary Team with 2 years of experience (BP). The ROIs were 
transferred to the perfusion maps and to the contrast enhance-
ment images calculated using equation 5. Mean whole-tumour 
CBF, uncorrected and corrected CBV, K2 and contrast enhance-
ment were calculated. Tumour size was calculated from the regis-
tered images by multiplying the number of voxels in the tumour 
ROI by the voxel volume. Further statistical analysis using SPSS 
(IBM v.24) was performed.
reSultS
Table  1 summarises the demographics, diagnosis along with 
neurofibromatosis Type 1 (NF1) status and any tumour treat-
ment prior to the DSC-ASL investigation for the 15 patients 
included in the study. The cohort comprised six female patients 
and nine male patients. The age range for the group was 1.6 to 
11.3 years. Low-grade gliomas included pilocytic astrocytoma 
(n = 7), a rosette-forming glio-neuronal tumour of the fourth 
ventricle (n = 1), atypical choroid plexus papilloma (n = 1) and 
pilomyxoid astrocytoma (n = 1). High-grade gliomas included 
glioblastoma (n = 1) and medulloblastoma (n = 1). A diagnosis 
of low-grade glioma was made by the Neuro-Oncology Multidis-
ciplinary Team on clinical and imaging grounds without a biopsy 
on three patients.
Table 2 shows mean ASL CBF and DSC CBV values – with and 
without leakage correction – and the percentage contrast agent 
enhancement as calculated from the pre- and post-contrast 
T1 weighted images. Percentage contrast agent enhancement 
is not shown for two of the 15 patients as one or more of the 
pre- or post-contrast images were not available for analysis. 
Mean K2 was positive in eight tumours indicating T1-dominant 
leakage; K2 was negative in four tumours indicating T2*-domi-
nant leakage and negligible in three tumours suggesting leakage 
was not an issue. In particular, two tumours with high levels 
of contrast enhancement had negative uncorrected CBV. On 
correction, both were found to have T1-dominant leakage with 
leakage correction resulting in a large increase in CBV and 
the highest positive K2 values of the cohort (tumour 1: CBV: 
−0.22 ml 100 g–1 to 2.13 ml 100 g–1, K2 = 0.64; tumour 2: 
Table 1. Patient cohort demographics
Sex Age (years) Tumour location Histology/diagnosis NF1a Surgery Chemotherapy
M 11.3 Thalamus Pilocytic astrocytoma Y Y
First: vincristine, carboplatin
Second: vinblastine
Third: vincristine actinomycin
M 8.8 Cerebellum
Rosette-forming 
glioneuronal tumour of 
fourth ventricle N Y
First: vincristine, carboplatin, etoposide
Second: erlotinib
F 4.8 Optic chiasm Pilocytic astrocytoma N Y
First: vincristine, carboplatin
Second vinblastine
M 3.9 Optic chiasm Pilocytic astrocytoma N Y
First vincristine, carboplatin, etoposide
Second vincristine actinomycin
M 2.8 Optic chiasm Pilocytic astrocytoma N N
First: vincristine, carboplatin
Second: vincristine, actinomycin
F 5.6 Optic pathway Pilocytic astrocytoma Y N
First: vincristine, carboplatin
Second: vincristine, actinomycin
F 1.6 Right parietal
Atypical choroid plexus 
papilloma N Y
Cyclophosphamide, etoposide, carboplatin, 
vincristine
M 2.1 Left hemispheric Glioblastoma N Y
First: carboplatin, etoposide, methotrexate, 
vincrisine, cyclophosphamide
Second bevacizumab, temozolomide
M 9.8 Cerebellum Medulloblastoma N N None
F 5.3 Optic pathway Low-grade glioma Y N
First: vincristine, carboplatin
Second vincristine, cyclophosphamide
M 1.7 Hypothalamus Pilocytic astrocytoma N Y Vincristine, carboplatin
M 1.6 Optic chiasm Pilocytic astrocytoma N Y Vincristine, carboplatin
F 3.7 Pons Low-grade glioma N N Vincristine, carboplatin
M 2.9 Optic chiasm Pilomyxoid astrocytoma N Y
First: vincristine, carboplatin
Second vinblastine
F 5.3 Cerebellar peduncle Low-grade glioma Y N None
aNF1 = neurofibromatosis Type 1.
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CBV = −0.30 ml 100 g–1 to 1.24 ml 100 g–1, K2 = 0.57). Two 
other tumours with high levels of contrast enhancement and low 
uncorrected CBV had similar results to a lesser degree. Tumours 
with low levels of enhancement and/or high uncorrected CBV 
had K2 values closer to zero (both positive and negative). Median 
K2 for the five most enhancing tumours was 0.12 (range = 0.08 to 
0.64) compared to 0.08 (range = −0.49 to 0.64) across the entire 
cohort. The median increase in CBV after leakage correction in 
this group was 52% as opposed to 23% in the remaining tumours.
The low-grade tumour in Figure 1 shows a high level of contrast 
agent uptake within the tumour which has caused CBV within 
the lesion to be underestimated when leakage correction is not 
applied, resulting in a void within the tumour on the uncorrected 
CBV map. When corrected heterogeneous CBV values are seen 
within the tumour, CBV values outside of the tumour are largely 
unaffected by the correction. High K2 values in the tumour 
compared to surrounding tissue reflect the amount of leakage 
correction required. Mean K2 was high at 0.64 demonstrating 
Table 2. Mean whole-tumour parameters. Presented are the mean values of CBF calculated from the ASL images, CBV values - 
both uncorrected and with leakage correction–and K2 from DSC imaging. The percentage amount of contrast enhancement as 
calculated from the pre- and post-contrast T1 images for 13 patients is shown (at least one of the pre- and post-contrast images 
were not available for two of the patients in the study)
Diagnosis Tumour volume cm3
CBF ml 100 
g–1 min–1
CBV uncorrected 
ml 100 g–1
CBV corrected 
ml 100 g–1 K2
Amount of contrast 
enhancement
Pilocytic astrocytoma 5.58 79.49 4.08 4.34 −0.49 107.0%
Rosette-forming 
glioneuronal tumour of 
fourth ventricle 22.38 63.91 1.79 3.30 0.36 –
Pilocytic astrocytoma 4.70 86.12 2.21 2.71 0.08 84.6%
Pilocytic astrocytoma 40.64 56.03 −0.22 2.13 0.64 109.7%
Pilocytic astrocytoma 28.02 52.50 1.33 2.77 0.41 52.2%
Pilocytic astrocytoma 4.70 48.21 1.26 1.85 0.16 5.2%
Atypical choroid plexus 
papilloma 1.40 10.94 2.33 2.49 −0.42 22.5%
Glioblastoma 33.45 10.24 1.76 1.89 −0.60 35.6%
Medulloblastoma 33.25 38.69 1.56 1.96 0.17 -
Low-grade glioma 3.19 82.62 3.81 4.06 0.26 23.1%
Pilocytic astrocytoma 24.87 21.57 1.02 1.29 0.05 12.7%
Pilocytic astrocytoma 30.32 23.54 1.29 1.96 0.12 128.1%
Low-grade glioma 10.68 74.63 2.41 2.68 0.04 10.2%
Pilomyxoid astrocytoma 1.12 20.22 −0.30 1.24 0.57 170.0%
Low-grade glioma 45.94 54.15 3.32 3.54 −0.36 7.8%
ASL, arterial spin labelling; CBF, cerebral blood flow; CBV, cerebral blood volume; DSC, dynamic susceptibility contrast;
Figure 1. Axial images from a 3-year-old male with a pilocytic astrocytoma. The patient had previously undergone surgery as well 
as first- and second-line chemotherapy. Shown from left to right are: post-contrast T1 weighted image showing vivid contrast 
enhancement in the tumour, uncorrected and corrected CBV maps produced from the DSC data and the K2 map for the same slice. 
Mean uncorrected and corrected tumour CBV were −0.22 ml 100 g–1 and 2.13 ml 100 g–1 respectively; mean K2 was 0.64 and mean 
contrast enhancement was 109.7%. CBV, cerebral blood volume; DSC, dynamic susceptibility contrast.
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the necessity for leakage correction. Good agreement is observed 
between CBF maps produced from ASL and leakage-corrected 
CBV maps (Figure 2).
A significant correlation was found between tumour CBF and 
patient age (r = 0.559, p = 0.030). No correlation was observed 
between age and uncorrected CBV (r = 0.434, p = 0.106) but 
was observed for the corrected (r = 0.560, p = 0.030) CBV data. 
Tumour volume was not found to correlate significantly with any 
other parameter. Median tumour volume was 22.4 cm3 (range = 
1.1–45.9 cm3). CBV values without the correction were consis-
tently lower than those which had undergone the Boxerman 
correction for leakage (median = 1.76 ml 100 g–1 vs 2.49 ml 100 
g–1 respectively). A paired t-test showed a significant difference 
between the corrected and non-corrected CBV values from the 
tumour ROI (p < 0.001). K2 values were variable (median = 0.16, 
range = −0.49–0.64) as were levels of contrast agent enhance-
ment (median = 35.6%, range = 5.2–170.0%) although the two 
parameters did not correlate significantly (r = 0.411, p = 0.163).
Mean tumour CBF calculated from the ASL images were tested 
against the mean tumour CBV values calculated from the DSC 
images to investigate correlations between the two methods as 
shown in Figure 3. A significant positive correlation was found 
between CBF and the uncorrected CBV (r = 0.516, p = 0.049) 
and a stronger correlation was found between CBF and corrected 
CBV (r = 0.728, p = 0.002).
DISCuSSIon
We have shown a significant correlation between CBV measured 
by DSC and CBF measured by ASL in children’s brain tumours. 
This correlation was improved when leakage correction was 
applied to the DSC data. When the blood brain barrier has been 
breached, contrast agent leaks from blood vessels resulting in 
T1 and T2* changes in the extracellular extravascular space. We 
employed both a pre-load of contrast agent and post-processing 
techniques to correct for these effects.16 The results suggest that 
ASL could be an alternative perfusion technique in paediatric 
patients where DSC data acquisition is difficult.
Across the patient cohort a significant difference in mean tumour 
CBV values with and without leakage correction was observed. 
Some tumours required more correction than others, reflected 
in the large range of K2 values shown in Table 2. We employed 
the Boxerman technique16 to correct DSC data but included the 
amendment present in19 where K2 was allowed to be either posi-
tive or negative. A positive K2 is associated with T1-dominant 
Figure 2. Axial images from a 4-year-old female with a pilo-
cytic astrocytoma treated with first- and second-line chemo-
therapy prior to MRI. Top-left: T2 weighted image, top-right: 
T1 weighted post-contrast image showing vivid contrast 
enhancement within the solid part of the tumour, bottom-left: 
CBF map derived from the ASL images and, bottom-right: 
leakage-corrected CBV map derived from the DSC images. 
ASL CBF was 86.12 ml 100 g–1 min–1; DSC leakage-corrected 
CBV was 2.71 ml 100 g. ASL, arterial spin labelling; CBF, cer-
ebral blood flow; CBV, cerebral blood volume; DSC, dynamic 
susceptibility contrast.
Figure 3. Plots showing the correlation between mean DSC 
CBV and ASL CBF values in tumour ROI. The top plot shows 
mean values taken from CBV maps without leakage correc-
tion (r = 0.516, p = 0.049). The bottom plot shows mean val-
ues taken from CBV maps with T1 and T2 correction (r = 0.728, 
p = 0.002). ASL, arterial spin labelling; CBF, cerebral blood 
flow; CBV, cerebral blood volume; DSC, dynamic susceptibility 
contrast; ROI, regions of interest.
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contrast agent leakage while a negative K2 is associated with 
T2*-dominant leakage. Tumours in our group were found to have 
a mixture of these effects.
Low-grade tumours, such as pilocytic astrocytomas, demon-
strating high enhancement on post-contrast T1 weighted images 
were often observed to have artificially low (sometimes nega-
tive or zero) uncorrected CBV values (Table 2), making clinical 
interpretation challenging. Following leakage correction in these 
tumours a large increase in CBV is observed and a large positive 
K2, indicating T1-dominant leakage19,28 was present requiring 
significant correction. This is illustrated in Figure 1 which shows 
an uncorrected and corrected CBV map. Once corrected and 
rescaled, more detail showing the heterogeneity and range of 
CBV values within the tumour is observed, K2 is large and posi-
tive and CBV has increased throughout the tumour.
Leakage effects have previously been investigated qualitatively for 
the grading of paediatric brain tumours, with the type of leakage 
as reflected by signal-intensity time curve shape–T1-dominant 
or T2*-dominant and return to baseline–being associated with 
low- and high-grade tumours respectively.28 This suggests that 
additional information is available from DSC-MRI data when 
leakage correction is applied.
Good agreement was observed between ASL CBF and DSC 
CBV maps. Although qualitative assessment is important from 
a radiological perspective it is important to develop quantitative 
imaging biomarkers that are robust.29 A recent paediatric brain 
tumour study showed no significant correlation between ASL 
and DSC metrics between tumours;25 however, correlations were 
shown for controls only, suggesting a problem only observed 
in tumour regions. No leakage correction was applied and the 
comparison in the tumours was made using CBF measured by 
both ASL and DSC. Questions still remain over the reliability of 
CBF measurements from DSC30 due to variations in how it is 
calculated, and CBV is still the most common DSC parameter 
presented in the literature. A recent study31 found a significant 
correlation between pre-treatment ASL CBF and DSC CBV in 
paediatric astrocytic tumours. Leakage correction was employed; 
however, the results of this were not reported.
The Boxerman technique, while fairly simple to implement, 
relies on having normal brain tissue within the imaging volume 
in order to correct leakage-affected contrast agent concentra-
tion-time curves. This may not always be possible especially 
with large brain tumours or where there is substantial oedema 
present. Other correction techniques have been presented in the 
literature.16,17,19 We also administered a pre-bolus of half the full 
contrast agent dose to all patients prior to the DSC measure-
ments to reduce T1 effects from contrast agent extravasation. 
Leakage effects resulting in difficult-to-interpret CBV maps were 
still observed, particularly in highly-enhancing tumours such 
as pilocytic astrocytomas, suggesting that the use of a pre-bolus 
is limited in this patient group. Currently there is no consensus 
on the optimal dose or timing of the pre-bolus administration 
although a recent study suggested that a second full dose was 
optimal.13 There is insufficient safety information to recommend 
this approach at present, particularly in children, and so we 
follow an internationally-accepted protocol for DSC-MRI in 
paediatric patients in Europe (International Society for Paedi-
atric Oncology Europe, SIOPE).
Our patient cohort was relatively small due to the challenges of 
performing multiple advanced imaging techniques on children. 
Insertion of venous cannulas in young children is difficult and 
central venous lines are not considered compatible with power 
injectors. Our patient cohort is relatively young, as younger 
patients are more likely to be scanned under general anaesthetic 
with a cannula in place. ASL measurements may have been 
improved by the normalisation of signal to unaffected tissue 
such as grey or white matter; however, this was difficult in some 
patients due to the large tumour sizes in them resulting in little 
healthy tissue within the ASL FOV. The subtraction analysis 
to assess levels of contrast agent enhancement was performed 
retrospectively with data acquired as part of clinical practice. 
For this reason, the timings between pre- and post-contrast T1 
acquisitions were not controlled and therefore variable between 
patients. This may explain why the level of enhancement did not 
always reflect the K2 value for a particular patient. Finally, the 
tumour group included in this study along with the treatments 
undergone prior to imaging is heterogeneous therefore the 
level of vessel leakage may not mirror that of a different cohort. 
However, many of the adjuvant treatments used in paediatric 
tumours, particularly chemotherapy for low-grade gliomas, have 
an antivascular effect and so we would expect vessel leakage 
correction to be even more important in untreated tumours. The 
results of this study show that no matter at what point in treat-
ment, if a tumour is enhancing, leakage correction is necessary to 
produce more accurate CBV values.
ConCluSIonS
In this study we have demonstrated the importance of leakage 
correction for DSC imaging of enhancing paediatric brain 
tumours and its use in both qualitative and quantitative assess-
ment. We found that CBF measured by ASL correlated well with 
CBV measured by DSC-MRI in paediatric brain tumours with 
the correlation improving once leakage correction had been 
applied. The amount of leakage correction required was highest 
in tumours showing high post-contrast T1 weighted enhance-
ment combined with low CBV. These tumours showed T1-dom-
inant leakage effects and large increases in CBV were observed 
following correction. We have also shown data that suggests a 
pre-bolus of contrast agent delivered prior to a DSC scan is not 
sufficient to reduce leakage effects alone, especially in highly-en-
hancing tumours. ASL is proving to be an alternative method for 
measuring perfusion in paediatric patients where DSC-MRI can 
prove challenging.
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